Isabelle Mouche, MSc

Isabelle obtained her Master in Pharmaceutical Industry from IPIM (Montpellier, France) in 1989. She has 20 years-experience in pharmaceutical companies R&D and 5 years-experience in CRO. She started working as a Researcher in in vitro toxicology Department at Synthelabo Recherche and sanofi. She developed and established cellular models as neuronal stem cells culture with gene markers analysis. Then she managed a team where in vitro mechanistic studies were performed for comprehensive understanding of toxicity. In 2010 she worked as Study Director in Cellular and Genetic toxicology Department at Covance. She supervised the implementation of dedicated cosmetic assays. In 2017, she co-founded GenEvolutioN offering innovative in vitro toxicology services in cytogenetics with telomere measurement for cellular therapy, personalized medicine and test article evaluation as chemicals, drugs, cosmetics and plant extracts.

Isabelle Mouche References

https://www.researchgate.net/profile/Isabelle_Mouche

https://www.linkedin.com/in/isabelle-mouche/

Mouche I, Malésic L and Gillardeaux O (2011) FETAX assay for evaluation of developmental toxicity. In Methods Molecular Biology, Vol 691,257-269.

Leconte I and Mouche I (2013) Frog embryo teratogenesis assay on Xenopus and predictivity compared with in vivo mammalian studies. In Methods Molecular Biology, Vol 947, 403-421.

 

 

 

Francis Finot, MSc

Francis Finot (MSC, EPHE) has more than 30 years-experience in pharmaceutical companies R&D and 5 years-experience in CRO (GLP). Study Director in Genetic Toxicology for more than 20 years, managed team where genetic and in vitro toxicology studies (screening and mandatory) were performed for pharmaceutical, cosmetic and chemical companies. He founds GenEvolutioN in 2017 offering innovative in vitro toxicology services in cytogenetics with telomere measurement for cellular therapy, personalized medicine and test article evaluation as chemicals, drugs, cosmetics and plant extracts.

Francis Finot References

https://www.researchgate.net/profile/Francis_Finot

https://www.linkedin.com/in/francisfinot/

Finot F, Kaddour A, Morat J, Mouche I, Zaguiad N, Cuceud C, Souverville D,, Négrault S, Cariou O, Essahli A, Prigent N,, Saule J, Paillard F, Heidingsfelde L, Lafouge P, Al Jawharib M, Hempeld WM, El May M, Colicchio B,, Dieterlen A,, Jeandidierh E, Sabatier L, Clements J and R. MˈKacher Genotoxic risk of ethyl-paraben could be related to telomere shortening Journal of Applied Toxiccology Nov., 2016

Finot F, Masson R, Desmots F, Ribault C,, Bichet N, Vericat JA, Lafouge P,1 Guguen-Guillouzo C, and Loyer P Combined Stimulation with the Tumor Necrosis Factor α and the Epidermal Growth Factor Promotes the Proliferation of Hepatocytes in Rat Liver Cultured Slices International Journal of Hepatology Volume 2012.

Paillard F, Finot F, Mouche I, Prenez A and Vericat JA. Use of Primary Cultures of Rat Hepatocytes to Predict Toxicity in the Early Development of New Chemical Entities. Toxicology in vitro 13: 693-700, 1999.

 

 

 

Radhia M’Kacher

Radhia M’Kacher (PhD-HDR), founder of Cell Environment company.

https://www.researchgate.net/profile/Radhia_Mkacher2

Dr M’kacher has worked in the field of radioprotection of population exposed to genotoxic agents for nearly 20 years directing projects focused on telomere dysfunction and DNA repair mechanisms. She began her career in Gustave Roussy cancer campus in the introduction of cytogenetic biological dosimetry in nuclear medicine. In the hematology department, she was promoted the predictive and prognostic factors in the occurrence of secondary cancer. In 2010, she joined commissariat of atomic energy (CEA), to participate in European project in low-dose radiation. Significant progress was made in telomere length quantification and chromosomal aberration scoring. In 2016, she created a biotechnology company, Cell Environment DNA damages R&D, to develop a new cytogenetic approachs in the detection of DNA damages. Dr. M’kacher eamed her PhD in radiobiology  and her HDR  at the University of Paris XI

Radhia M’Kacher References

M’Kacher R, Andreoletti L, Flamant S, Milliat F, Girinsky T, et al. 2010. JC human polyomavirus is associated to chromosomal instability in peripheral blood lymphocytes of Hodgkin’s lymphoma patients and poor clinical outcome. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 21: 826-32

M’Kacher R, Benneceur-Griscelli A, Girinsky T, Koscielny S, Delhommeau F, et al. 2007. Telomere shortening and associated chromosomal instability in peripheral blood lymphocytes of patients with Hodgkin’s lymphoma prior to any treatment are predictive of second cancers. International journal of radiation oncology, biology, physics 68: 465-71

M’Kacher R, Legal JD, Schlumberger M, Aubert B, Beron-Gaillard N, et al. 1997. Sequential biological dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma. Journal of nuclear medicine: official publication, Society of Nuclear Medecine 38:377-80

M’Kacher R, Maalouf EE, Ricoul M, Heidingsfelder L, Laplagne E, et al. 2014. New tool for biological dosimetry: reevaluation and automation of the gold standard method following telomere and centromere staining. Mutation research 770: 45-53

Other publications

Cariou O, Laroche-Prigent N, Ledieu S, Guizon I, Paillard F, Thybaud V. 2010. Cytosine arabinoside, vinblastine, 5-fluorouracil and 2-aminoanthracene testing in the in vitro micronucleus assay with L5178Y mouse lymphoma cells at Sanofi Aventis, with different cytotoxicity measurements, in support of the draft OECD Test Guideline on In vitro Mammalian Cell Micronucleus Test. Mutation research 702: 148-56